Applications for Leave

Decision Information

Decision Content

No. 40100     

 

 

September 29, 2022

 

Le 29 septembre 2022

 

 

 

 

BETWEEN:

 

Pharmascience Inc.

Applicant

- and -

 

Teva Canada Innovation, Teva Canada Limited and Yeda Research and Development Co., Ltd

Respondents

AND BETWEEN:

 

Pharmascience Inc.

Applicant

- and -

 

Teva Canada Innovation, Teva Canada Limited and Yeda Research and Development Co., Ltd

Respondents

 

 

 

AND BETWEEN:

 

Pharmascience Inc.

Applicant

- and -

 

Teva Canada Innovation, Teva Canada Limited and Yeda Research and Development Co., Ltd

Respondents

 

 

ENTRE :

 

Pharmascience Inc.

Demanderesse

- et -

 

Teva Canada Innovation, Teva Canada Limited et Yeda Research and Development Co., Ltd

Intimées

ET ENTRE :

 

Pharmascience Inc.

Demanderesse

- et -

 

Teva Canada Innovation, Teva Canada Limited et Yeda Research and Development Co., Ltd

Intimées

 

 

 

ET ENTRE :

 

Pharmascience Inc.

Demanderesse

- et -

 

Teva Canada Innovation, Teva Canada Limited et Yeda Research and Development Co., Ltd

Intimées

 

 

 

JUDGMENT

 

The motion to join three Federal Court of Appeal files in a single application for leave to appeal is granted. The application for leave to appeal from the judgment of the Federal Court of Appeal, Numbers A-315-20, A-316-20 and A-4-21, 2022 FCA 2, dated January 6, 2022, is dismissed with costs.

 

 

 

JUGEMENT

 

La requête pour joindre trois dossiers de la Cour d’appel fédérale dans une seule demande d’autorisation d’appel est accueillie. La demande d’autorisation d’appel de l’arrêt de la Cour d’appel fédérale, numéros A-315-20, A-316-20 et A-4-21, 2022 FCA 2, daté du 6 janvier 2022, est rejetée avec dépens.

 

 

 

 

 

J.S.C.C.

J.C.S.C.

 

 You are being directed to the most recent version of the statute which may not be the version considered at the time of the judgment.